The Barcelona Centre for International Health Research, CRESIB is a global health research institute developed from some of the leading academic and biomedical research institutions in Barcelona (Universitat de Barcelona, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) together with the Catalan Government as a response to the new international health challenges of the 21st century.

Consult here our research areas and programmes

News

  • Experts discuss the advances in the fight against malaria

    Central america is identified as a priority where decisive action could completely eradicate malaria. [+]

  • Spain's leadership crucial in advances against malaria over the last decade

    Preliminary data from an ISGlobal study indicates that Spain's contribution has helped save the lives of an estimated 100,000 children over the last eight years. [+]

  • World malaria day, keeping up the momentum

    ISGlobal and the Ramón Areces foundation are organising a special symposium entitled "The Spanish contribution to the fight against malaria and the elimination effort" to celebrate world malaria day 2012. [+]

  • "We Are Living Through a Great Revolution in Global Health"

    Pedro Alonso, director of CRESIB and ISGlobal, and researchers Antoni Trilla and Ned Hayes have contributed their scientific knowledge to Epidemia!—an exhibition on the subject of epidemics that opened yesterday in Barcelona. [+]

  • Investigators Demonstrate That Intermittent Preventive Treatment in Infants is Effective Against Malaria in a Non-African Setting

    PLoS Medicine publishes the result of a trial in Papua New Guinea led by a researcher from CRESIB, Ivo Mueller. [+]

  • Progress in the Tuberculosis Vaccine Trial

    CRESIB and the CISM conduct a multicentre trial aimed to test the efficacy of the Aeras 402 tuberculosis vaccine in infants. [+]

  • CRESIB Scientists Discover Key Information About the Malaria Parasite

    The journal Genome Research has published a study that adds to our understanding of the biology of the malaria parasite and opens the door to the development of new tools to fight this disease. [+]

  • New Master of Global Health ISGlobal-CRESIB-UB

    Pre-enrollment for the first edition of the new Master of Global Health is already open. This training programme is a collaboration among ISGlobal-CRESIB and the Universitat de Barcelona (UB) [+]

  • CRESIB highlights the lack of political will to address the problem of maternal mortality

    On International's Women's Day, CRESIB and the Barcelona Institute for Global Health call for a greater gender focus in medical research [+]

  • Good news at the 8th workshop on Imported Chagas Disease

    Participants welcome the announcement that production of Benznidazole, the main treatment of choice for Chagas disease, is underway in Argentina [+]

  • New source of Benznidazole, the first line treatment for Chagas disease

    After months of inventory shortages, the Fundación Mundo Sano and ISGlobal-CRESIB announce the production of a new generic version of Benznidazole [+]

  • Eighth World Congress on Vaccines, Immunisation and Immunotherapy

    The eighth edition of the World Congress on Vaccines, Immunisation and Immunotherapy will be held in Barcelona (Spain) from 5 -7 June 2012. [+]

  • Recruitment phase of malaria in pregnancy trial completed

    The aim of the MiPPAD trials is to contribute to the development of new clinical interventions to reduce the incidence and effects of malaria in pregnancy [+]

  • Pedro Alonso: “Investment in research generates wealth”

    The Director of CRESIB takes part in a science outreach day on the subject of the malaria vaccine at CosmoCaixa in Barcelona. The RTS,S vaccine is expected to be ready by 2014 [+]

  • CRESIB scientists make hey breakthrough that could lead to the eradication of a neglected disease: Yaws

    The Lancet magazine publishes a study in which CRESIB researchers based in Papua New Guinea demonstrate the efficacy of a new oral treatment for yaws [+]

  • RTS,S malaria vaccine selected as one of the top ten medical breakthroughs in 2011

    Pedro Alonso points out that the results published in 2011 are the product of more than a decade of work [+]

  • The first results from ongoing Phase III trial show that malaria vaccine candidate RTS,S reduces the risk of malaria by half in African children aged 5 to 17 months

    The largest clinical trial in children ever conducted in Africa [+]

Job Opportunities

  • Call for rotations of resident doctors and graduated professionals in the Manhiça Health Research Centre (CISM)

    More information [+]

  • Call for short stays of students in the Manhiça Health Research Centre (CISM)

    More information [+]

  • Molecular Parasitologist

    More information  [+]

  • Pre-doctoral Fellow

    More information [+]

  • Doctorate fellowship in Malaria Immunopathology

    More information [+]

  • Generalitat de Catalunya
  • Clínic Barcelona - Hospital Universitari
  • IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer
  • UB - Universitat de Barcelona